摘要
目的筛选前列腺癌的差异表达基因,探讨前列腺癌关键基因的相关分子机制及其临床预后的意义。方法利用美国基因表达综合数据库(American gene expression comprehensive database,GEO)下载三组目标的前列腺癌组织及前列腺组织中mRNA转录组数据。通过癌组织及良性组织的差异表达基因表达谱、GO分析及KEGG通路富集分析,外部验证选定的关键基因与临床预后的关系。结果差异表达基因生物过程主要在减数分裂和三价铁结合、氧化还原酶等功能富集。筛选出的前6位上调表达的关键基因为PCA3,SIM2,AMACR,HOXC6,ERG和TOP2A。PCA3和TOP2A具有良好的相关性和临床预测意义。结论PCA3和TOP2A有望成为潜在的前列腺癌肿瘤标志物。
Objective To screen and analyze differentially expressed genes in prostate cancer and explore their related molecular mechanism and the significance of clinical prognosis.Methods The mRNA transcriptome data of the prostate cancer tissue and the benign tissue was downloaded from the database of the American gene expression comprehensive database(GEO).By gene expression profiling,GO and KEGG pathway enrichment analysis of the differentially expressed genes,the hub genes were obtained,and the relationship between the hub genes and their clinical prognosis were further analyzed.Results The biological processes of differentially expressed genes were mainly enriched in the meiotic cell cycle,the ferric iron binding,and the oxidoreductase activity.The hub genes were PCA3,SIM2,AMACR,HOXC6,ERG,and TOP2A.PCA3 and TOP2A had a good correlation and clinical predictive significance.Conclusion PCA3 and TOP2A might be the biomarkers of prostate cancer.
作者
杨智
米军
Yang Zhi;Mi Jun(Research Institute of Urology,Key Laboratory of Gansu Province for Urological Diseases,Clinical Medical Center of Gansu Province for Urological Diseases,Lanzhou University Second Hospital,Gansu,China)
出处
《中国男科学杂志》
CAS
CSCD
2022年第4期47-52,61,共7页
Chinese Journal of Andrology
